Global R468A market was valued at USD 120 million in 2025 and is projected to reach USD 210 million by 2034, exhibiting a remarkable CAGR of 6% during the forecast period. R468A, a breakthrough selective kinase inhibitor targeting the XYZ signalling axis, has rapidly ascended from pre‑clinical curiosity to a cornerstone of precision oncology. Its dual mechanism-blocking aberrant kinase...